RU2015146418A - Библиотека синтетических специфически связывающих молекул - Google Patents

Библиотека синтетических специфически связывающих молекул Download PDF

Info

Publication number
RU2015146418A
RU2015146418A RU2015146418A RU2015146418A RU2015146418A RU 2015146418 A RU2015146418 A RU 2015146418A RU 2015146418 A RU2015146418 A RU 2015146418A RU 2015146418 A RU2015146418 A RU 2015146418A RU 2015146418 A RU2015146418 A RU 2015146418A
Authority
RU
Russia
Prior art keywords
antigen
specific antigen
binding molecule
seq
dna sequences
Prior art date
Application number
RU2015146418A
Other languages
English (en)
Russian (ru)
Other versions
RU2015146418A3 (https=
Inventor
Каролин Джейн БАРЕЛЛЕ
Уильям Джеймс Джонатан ФИНЛЕЙ
Альфредо ДАРМАНИН-ШИАН
Эндрю Джастин Редклифф ПОРТЕР
Original Assignee
Зе Юниверсити Корт Оф Зе Юниверсити Оф Абердин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Юниверсити Корт Оф Зе Юниверсити Оф Абердин filed Critical Зе Юниверсити Корт Оф Зе Юниверсити Оф Абердин
Publication of RU2015146418A publication Critical patent/RU2015146418A/ru
Publication of RU2015146418A3 publication Critical patent/RU2015146418A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
RU2015146418A 2013-04-23 2014-04-23 Библиотека синтетических специфически связывающих молекул RU2015146418A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361815043P 2013-04-23 2013-04-23
US61/815,043 2013-04-23
PCT/EP2014/058251 WO2014173959A2 (en) 2013-04-23 2014-04-23 Synthetic library of specific binding molecules

Publications (2)

Publication Number Publication Date
RU2015146418A true RU2015146418A (ru) 2017-05-26
RU2015146418A3 RU2015146418A3 (https=) 2018-05-07

Family

ID=50543598

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015146418A RU2015146418A (ru) 2013-04-23 2014-04-23 Библиотека синтетических специфически связывающих молекул
RU2015146419A RU2015146419A (ru) 2013-04-23 2014-04-23 Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015146419A RU2015146419A (ru) 2013-04-23 2014-04-23 Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl

Country Status (11)

Country Link
US (3) US10472410B2 (https=)
EP (3) EP3683312B1 (https=)
JP (2) JP6616284B2 (https=)
KR (2) KR20160010466A (https=)
CN (2) CN105531370A (https=)
AU (3) AU2014257549B2 (https=)
BR (2) BR112015026729A2 (https=)
CA (2) CA2909921C (https=)
DK (1) DK2989203T3 (https=)
RU (2) RU2015146418A (https=)
WO (2) WO2014173959A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151658A1 (en) 2012-05-07 2023-03-22 Elasmogen Limited Single domain binding molecule
JP6616284B2 (ja) 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー
EP3160995A2 (en) 2014-06-26 2017-05-03 Ossianix Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
EP3215531A1 (en) * 2014-11-03 2017-09-13 Merck Patent GmbH Methods for generating bispecific shark variable antibody domains and use thereof
EP3218411B1 (en) 2014-11-14 2022-01-12 Ossianix, Inc. Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
CN107130300A (zh) * 2016-10-08 2017-09-05 深圳劲宇生物科技有限公司 一种dna编码分子库的合成方法及dna模板
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11919949B2 (en) 2017-09-27 2024-03-05 Elasmogen Ltd Specific binding molecules
US11180544B2 (en) * 2017-11-07 2021-11-23 City University Of Hong Kong Method of producing antibody fragment
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
CN111197074B (zh) * 2018-11-20 2023-08-15 深圳华大生命科学研究院 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用
WO2020167872A1 (en) * 2019-02-11 2020-08-20 Woodbury Neal W Systems, methods, and media for molecule design using machine learning mechanisms
GB201906997D0 (en) * 2019-05-17 2019-07-03 Elasmogen Ltd Conjugates
GB201908886D0 (en) * 2019-06-20 2019-08-07 Almac Discovery Ltd Anthracycline derivatives
CN116457368A (zh) * 2020-05-01 2023-07-18 匹兹堡大学联邦高等教育系统 用于鉴定纳米抗体和纳米抗体亲和力的组合物和方法
CN112301431B (zh) * 2020-08-12 2023-01-31 华东理工大学 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
GB202020154D0 (en) * 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
GB202020152D0 (en) 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4141028A1 (en) 2021-08-31 2023-03-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US20050053989A1 (en) * 2003-08-27 2005-03-10 Gil Sharon Libraries of recombinant chimeric proteins
JP2008511286A (ja) 2004-06-02 2008-04-17 ダイアテック・ピーティワイ・リミテッド サメ類のＩｇＮＡＲドメインに基づく結合成分
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2006003999A1 (ja) * 2004-07-05 2006-01-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
CA2602035C (en) * 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
JP5171611B2 (ja) 2005-03-25 2013-03-27 ナショナル リサーチ カウンシル オブ カナダ 可溶性ポリペプチドの単離方法
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
EP2397498A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
ATE536369T1 (de) 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
WO2009026638A1 (en) 2007-08-31 2009-03-05 Melbourne Health Marine-animal derived therapeutic and diagnostic agents for hepatitis b
AU2009301631A1 (en) 2008-10-06 2010-04-15 Commonwealth Scientific And Industrial Research Organisation Amyloid-beta peptide crystal structure
WO2010040174A1 (en) * 2008-10-07 2010-04-15 Zap Holdings Pty Ltd Synchronization of relational databases with olap cubes
WO2011056056A2 (es) 2009-11-04 2011-05-12 Laboratorios Silanes, S.A. De C.V. Dominios vhnar anti -citocinas
EP2646461A2 (en) 2010-12-03 2013-10-09 Cyclogenix Ltd VARIANTS OF igNAR
EP4151658A1 (en) * 2012-05-07 2023-03-22 Elasmogen Limited Single domain binding molecule
CN103031304A (zh) * 2012-12-27 2013-04-10 苏州大学 一种微小rna用于调控b7-h2基因表达
JP6616284B2 (ja) 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー

Also Published As

Publication number Publication date
US10202438B2 (en) 2019-02-12
AU2014257565A1 (en) 2015-11-26
JP6591964B2 (ja) 2019-10-16
AU2014257549B2 (en) 2019-04-18
CA2909921A1 (en) 2014-10-30
AU2019206064A1 (en) 2019-08-08
JP2016524463A (ja) 2016-08-18
WO2014173975A1 (en) 2014-10-30
EP3683312B1 (en) 2022-09-07
KR102320189B1 (ko) 2021-11-03
US10472410B2 (en) 2019-11-12
WO2014173959A2 (en) 2014-10-30
RU2015146419A (ru) 2017-05-26
US20160068600A1 (en) 2016-03-10
WO2014173959A3 (en) 2015-01-29
EP2989203B1 (en) 2019-11-13
US20200002403A1 (en) 2020-01-02
US20160176951A1 (en) 2016-06-23
CN105492610A (zh) 2016-04-13
CN105492610B (zh) 2020-08-25
EP2989204A1 (en) 2016-03-02
EP2989204B1 (en) 2019-03-20
BR112015026729A2 (pt) 2017-09-05
KR20160010466A (ko) 2016-01-27
AU2014257549A1 (en) 2015-11-26
KR20160015220A (ko) 2016-02-12
US11459377B2 (en) 2022-10-04
RU2015146418A3 (https=) 2018-05-07
CA2909923A1 (en) 2014-10-30
EP3683312A2 (en) 2020-07-22
DK2989203T3 (da) 2020-02-17
BR112015026716A2 (pt) 2017-09-05
JP2016524592A (ja) 2016-08-18
EP2989203A2 (en) 2016-03-02
CN105531370A (zh) 2016-04-27
JP6616284B2 (ja) 2019-12-04
CA2909921C (en) 2022-12-06
EP3683312A3 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
RU2015146418A (ru) Библиотека синтетических специфически связывающих молекул
Arbabi-Ghahroudi Camelid single-domain antibodies: promises and challenges as lifesaving treatments
JP2016524463A5 (https=)
CN106604932B (zh) 人白细胞介素-2的免疫刺激单克隆抗体
JP5047996B2 (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
JP2022531113A (ja) 組換えポリクローナルタンパク質およびその使用方法
Hanke et al. Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies
RU2019118359A (ru) Антитело к cd73 человека
JP2016524592A5 (https=)
JP2020505001A (ja) 抗ｂｃｍａ重鎖のみ抗体
CN107667115A (zh) 针对埃博拉病毒糖蛋白的人抗体
KR102504884B1 (ko) Sftsv에 결합 가능한 나노 항체 및 이의 응용
RU2017107773A (ru) Антитела, специфичные к ммр9
JP2019503990A (ja) 改良された血清アルブミン結合剤
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
BR112021003410A2 (pt) anticorpos de domínio único anti-bcma, grupo de genes dos ditos anticorpos, polipeptídeo, vetor de expressão, célula hospedeira, receptor de antígeno quimérico, célula t modificada pelo mesmo, composição farmacêutica e usos dos ditos anticorpos
JP2014534806A5 (https=)
CN112004830B (zh) 拮抗性pd-1、pd-l1和lag-3结合蛋白
Silva-Pilipich et al. A small virus to deliver small antibodies: new targeted therapies based on AAV delivery of nanobodies
CN101851291A (zh) 一种抗人baff单克隆抗体的重链和轻链可变区
KR20210143804A (ko) 혈액암 및 고형 종양암의 치료를 위한 키메라 항원 수용체 변형된 t 세포 (car-t)
JP2021517459A5 (https=)
KR20180020142A (ko) Iii형 분비계 표적화 분자
KR102654105B1 (ko) 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
Isaacs et al. A nanobody-based therapeutic targeting Nipah virus limits viral escape

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180822